REG-Genmab to Present Results from Comprehensive Epcoritamab Development Program Highlighting Potential Across B-Cell Malignancies at the 2026 American Society of Hematology (ASH) Annual Meeting
Key Highlights
- ➤22 abstracts showcase epcoritamab across B-cell malignancies and treatment lines
- ➤EPCORE DLBCL-4 will disclose Phase 3 primary results for epcoritamab plus lenalidomide
- ➤EPCORE FL-1 provides updated subgroup analyses for epcoritamab plus rituximab and lenalidomide
- ➤Genmab hosts its 2026 R&D Update and ASH Data Review on December 16
Expert Statements
Judith Klimovsky, Executive Vice President and Chief Development Officer of Genmab
“The range of studies accepted for presentation at this year’s American Society of Hematology Annual Meeting reflects our commitment to exploring the full utility of epcoritamab and reinforces our confidence in epcoritamab’s potential to become a core therapy across B-cell malignancies, as a monotherapy and in combination with other medicines across lines of treatment”
Judith Klimovsky, Executive Vice President and Chief Development Officer of Genmab
“Together with our partner AbbVie, we look forward to sharing these findings with the global hematology community and further exploring what they could mean for patients.”
COPENHAGEN, Denmark; November 4, 2026 * Twenty-two abstracts underscore the versatility of epcoritamab as monotherapy and in combination across multiple disease subtypes and in earlier lines of therapy * Six oral presentations include first data disclosure from the Phase 3 EPCORE(®) DLBCL-4 study evaluating epcoritamab in combination with lenalidomide in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) Genmab A/S (Nasdaq: GMAB) announced today that 22 abstracts evaluating epcoritamab, a subcutaneous T-cell engaging bispecific antibody, will be presented or published at the 68(th) Annual Meeting and Exposition of the American Society of Hematology (ASH), taking place December 12-15, 2026, in New Orleans, Louisiana, and virtually.
The breadth of data to be shared at ASH reflects continued progress across the comprehensive epcoritamab development program, including its evaluation in earlier lines of therapy and combination regimens across multiple B-cell malignancies. Highlights include the first presentation of the primary results from the Phase 3 EPCORE(®) DLBCL-4 study evaluating fixed duration epcoritamab plus lenalidomide in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). The results from EPCORE DLBCL-4 will also be highlighted in the ASH 2026 Press Program.
Get started
Create a free account to read the full story.